Investigational Site Number :7240003

Barcelona, Barcelona [Barcelona] 08041

2 studies enrolling now · 10 studies all time

What they study most

Breast Cancer, Bronchiectasis, Chronic Rhinosinusitis Without Nasal Polyps, Chronic Spontaneous Urticaria, Congenital Cystic Kidney Disease, Gastric Cancer, Hidradenitis Suppurativa, Lichen Simplex Chronicus, Lung Neoplasm Malignant, Lung Transplant Rejection, Neoplasm, Neoplasm Malignant

Studies at this site

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) — Recruiting now
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction — Recruiting now
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1) — Running, not enrolling
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps — Running, not enrolling
A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis — Completed
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa — Completed
Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat — Stopped early
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors — Stopped early
Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID) — Completed
Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients — Completed